These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 28270103)

  • 1. Angiotensin II receptor blockers and risk of acute pancreatitis - a population based case-control study in Sweden.
    Bexelius TS; Ljung R; Mattsson F; Lu Y; Lindblad M
    BMC Gastroenterol; 2017 Mar; 17(1):36. PubMed ID: 28270103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of oral glucocorticoid use with an increased risk of acute pancreatitis: a population-based nested case-control study.
    Sadr-Azodi O; Mattsson F; Bexlius TS; Lindblad M; Lagergren J; Ljung R
    JAMA Intern Med; 2013 Mar; 173(6):444-9. PubMed ID: 23440105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polypharmacy and risk of acute pancreatitis.
    Razavi D; Lindblad M; Bexelius T; Oskarsson V; Sadr-Azodi O; Ljung R
    Pharmacoepidemiol Drug Saf; 2016 Nov; 25(11):1337-1341. PubMed ID: 27651204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular disease and risk of acute pancreatitis in a population-based study.
    Bexelius TS; Ljung R; Mattsson F; Lagergren J
    Pancreas; 2013 Aug; 42(6):1011-5. PubMed ID: 23851434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of angiotensin II receptor blockers and the risk of acute pancreatitis: a nested case-control study.
    Sjöberg Bexelius T; García Rodríguez LA; Lindblad M
    Pancreatology; 2009; 9(6):786-92. PubMed ID: 20110746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ACE inhibitors and the risk of acute pancreatitis-a population-based case-control study.
    Kuoppala J; Enlund H; Pulkkinen J; Kastarinen H; Jyrkkä J; Happonen P; Paajanen H
    Pharmacoepidemiol Drug Saf; 2017 Jul; 26(7):853-857. PubMed ID: 28247528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased risk of acute pancreatitis among tetracycline users in a Swedish population-based case-control study.
    Ljung R; Lagergren J; Bexelius TS; Mattsson F; Lindblad M
    Gut; 2012 Jun; 61(6):873-6. PubMed ID: 21957155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and the risk of developing rheumatoid arthritis in antihypertensive drug users.
    de Jong HJ; Vandebriel RJ; Saldi SR; van Dijk L; van Loveren H; Cohen Tervaert JW; Klungel OH
    Pharmacoepidemiol Drug Saf; 2012 Aug; 21(8):835-43. PubMed ID: 22674737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preadmission use of renin-angiotensin blockers and rupture of abdominal aortic aneurysm: a nationwide, population-based study.
    Wemmelund H; Høgh A; Hundborg HH; Johnsen SP; Lindholt JS
    Pharmacoepidemiol Drug Saf; 2016 Feb; 25(2):141-50. PubMed ID: 26817783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acid-suppressing drugs and gastroesophageal reflux disease as risk factors for acute pancreatitis--results from a Swedish Case-Control Study.
    Sundström A; Blomgren K; Alfredsson L; Wiholm BE
    Pharmacoepidemiol Drug Saf; 2006 Mar; 15(3):141-9. PubMed ID: 16200654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EFFECT OF SYSTEMIC BETA-BLOCKERS, ACE INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS ON DEVELOPMENT OF CHOROIDAL NEOVASCULARIZATION IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION.
    Thomas AS; Redd T; Hwang T
    Retina; 2015 Oct; 35(10):1964-8. PubMed ID: 25996426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of statins and the risk of acute pancreatitis: a population-based case-control study.
    Kuoppala J; Pulkkinen J; Kastarinen H; Kiviniemi V; Jyrkkä J; Enlund H; Happonen P; Paajanen H
    Pharmacoepidemiol Drug Saf; 2015 Oct; 24(10):1085-92. PubMed ID: 26300102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, and risk of appendicitis.
    Mukamal KJ; Ghimire S; Pandey R; Fiarman GS; Gautam S
    Ann Epidemiol; 2012 Oct; 22(10):747-50. PubMed ID: 22867943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers and pneumonia risk among stroke patients.
    Liu CL; Shau WY; Wu CS; Lai MS
    J Hypertens; 2012 Nov; 30(11):2223-9. PubMed ID: 22929610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statins and the risk of acute pancreatitis: a population-based case-control study.
    Thisted H; Jacobsen J; Munk EM; Nørgaard B; Friis S; McLaughlin JK; Sørensen HT; Johnsen SP
    Aliment Pharmacol Ther; 2006 Jan; 23(1):185-90. PubMed ID: 16393296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockers of Angiotensin Other Than Olmesartan in Patients With Villous Atrophy: A Nationwide Case-Control Study.
    Mårild K; Lebwohl B; Green PH; Murray JA; Ludvigsson JF
    Mayo Clin Proc; 2015 Jun; 90(6):730-7. PubMed ID: 26046408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on major adverse cardiac events in patients with newly diagnosed type 2 diabetes: a nationwide study.
    Shih CJ; Chu H; Ou SM; Chen YT
    Int J Cardiol; 2015 Nov; 199():283-9. PubMed ID: 26218587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction Patients With Renal Dysfunction.
    Evans M; Carrero JJ; Szummer K; Åkerblom A; Edfors R; Spaak J; Jacobson SH; Andell P; Lindhagen L; Jernberg T
    J Am Coll Cardiol; 2016 Apr; 67(14):1687-97. PubMed ID: 27056774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renin angiotensin system blockers-associated angioedema in the Thai population: analysis from Thai National Pharmacovigilance Database.
    Win TS; Chaiyakunapruk N; Suwankesawong W; Dilokthornsakul P; Nathisuwan S
    Asian Pac J Allergy Immunol; 2015 Sep; 33(3):227-35. PubMed ID: 26342120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No increase in adverse events during aliskiren use among ontario patients receiving angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers.
    Gilbert CJ; Gomes T; Mamdani MM; Hellings C; Yao Z; Garg AX; Wald R; Harel Z; Juurlink DN
    Can J Cardiol; 2013 May; 29(5):586-91. PubMed ID: 23541666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.